hyperCORE International

For Sponsors & CROs

Connect with us

As a vast network of experts in our field, we believe coming together is the key to accelerating research.

hyperCORE International offers the ability to conduct research across all therapeutic areas, providing a vast network of leading clinical research sites committed to the highest standard of excellence in enrollment, data integrity, and timelines. Our network features over 120 research site locations across North and South America, multiple hospital affiliations, remote and mobile units, and expertise in device and therapeutics of all phases of research.  Our partner sites have special expertise and key opinion leaders in endocrine and metabolic studies inclusive of NASH and have on-site FibroScan® machines in many of our locations. They are leading industry representatives in vaccine research including the Clinical Trial Site of the Year for Vaccine Research. Our network also offers broad dermatology expertise with access to more than 1 million patient lives and various medical indications to offer research as a pathway to clinical care.

Our ability to move beyond the constraints and challenges is reflected in our robust clinical trial experience. Our patients are exceptionally diverse in health status, age, race, ethnicity, sex, and co-morbidities. We have enabled our sites to scale quickly to accommodate large volume trials by using shared resources and platforms resulting in rapid study start-up delivery and execution. With hyperCORE’s collaborative approach to clinical research partnership, research has never been more streamlined.

Therapeutic Areas
Cannabis & Psychedelics
Cardiology
COVID- 19 Capabilities
Dermatology Capabilities
Devices / Diagnostics
Endocrinology
Gastroenterology
Gerontology
Gynecology
Hematology
NASH Capabilities
Immunology
Men’s Health
Nephrology
Neurology
Nutrition
Oncology
Ophthalmology
Pain Management
Pediatrics
Podiatry
Psychiatry
Pulmonology
Rheumatology
Smoking Cessation
Urology
Vaccine Capabilities

Phase 1 Therapeutics

Nine Phase 1 capable sites in 14 locations in the United States and Canada with 23 Principal Investigators

Collectively conducted 55 Phase 1 trials - 21 were first-in human trials

Overnight capabilities in 8 locations with 107 beds combined. Facilities range from 4,000 to 17,000 SF

On-site pharmacies at 6 sites; PBMC capabilities at 5 sites

Phase 1 Testing / Equipment